TOTAL COMPANY

WORLDWIDE SALES

Q4 $11.5B
FULL YEAR $43.1B
FULL YEAR $5.21†

GROWTH ON AN ORGANIC BASIS*

Q4 +7.7%¹
FULL YEAR +22.9%²
REFLECTS NEARLY 43% GROWTH VERSUS PRIOR YEAR

BUSINESS HIGHLIGHTS

LEADING IN HEALTH TECH

>$1.0B Q4 FREESTYLE LIBRE® SALES
Now approaching 4 million users globally

15.8%³ GROWTH IN MEDICAL DEVICES
on an organic basis* compared to pre-pandemic sales in 2019

FULL-YEAR 2021: KEY BUSINESS UNITS³
GROWTH ON AN ORGANIC BASIS*

+19.4% MEDICAL DEVICES
+42.7% DIAGNOSTICS
+7.7% NUTRITION
+10.4% ESTABLISHED PHARMACEUTICALS

ISSUED FULL-YEAR 2022 EPS GUIDANCE

AT LEAST $4.70⁶ IN ADJUSTED DILUTED EPS
REFLECTS 45%⁷ GROWTH COMPARED TO 2019

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.